Develops topical drug candidates for rare and orphan diseases, including skin treatments for people with Netherton Syndrome and Peeling Skin Syndrome.
10-K for FY2025, filed Mar 26, 2026We are a late-stage clinical specialty pharmaceutical company focused on the development and commercialization of therapeutic products that…View ↗
Our Product CandidatesView ↗
QRX003 is also being developed as a potential treatment for Peeling Skin Syndrome, a rare genetic skin disease for which there is no…View ↗
No revenue reported yet.
10-K for FY2025, filed Mar 26, 2026
The company is developing treatments for patients with rare and orphan diseases, and plans to sell directly in the U.S., Europe and Japan while using distribution partners in other territories.
10-K for FY2025, filed Mar 26, 2026
10-Q for Q3 FY2026, filed Nov 5, 2026
−$4.9MView ↗
8-K, filed Nov 6, 2026
Positive Interim Data from Phase 2/3 Study CL-QRX003-004. On August 28, 2026, Quoin reported positive interim results from CL-QRX003-004…View ↗
8-K, filed Oct 14, 2026
EMA Grants Orphan Drug Designation to QRX003 for Treatment of Peeling Skin SyndromeView ↗
8-K, filed Aug 28, 2026
On August 27, 2026, Quoin Pharmaceuticals Ltd. (the “Company” or “Quoin”) entered into a Securities Purchase Agreement (the “Purchase…View ↗
Pipeline focus
The older report also described a candidate for a blistering skin disease and a research-stage candidate for Netherton Syndrome. The latest report focuses on a topical lotion for Netherton and Peeling Skin syndromes and topical rapamycin formulations.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 26, 2026We are a clinical stage specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products that…View ↗
QRX004View ↗
In November 2021, we entered into the Research Agreement with QUT, pursuant to which we have an option to in-license the QRX007 product.…View ↗
We are a late-stage clinical specialty pharmaceutical company focused on the development and commercialization of therapeutic products that…View ↗
QRX003 is also being developed as a potential treatment for Peeling Skin Syndrome, a rare genetic skin disease for which there is no…View ↗
On June 10, 2024 we signed a research agreement with UCC. The scope of the agreement encompasses the development of novel topical…View ↗
Competes with LifeMax Laboratories, Sixera Pharmaceuticals, ResVita Bio, BioCryst, and Azitra
10-K for FY2025, filed Mar 26, 2026The clinical biotechnology industry is a competitive industry characterized by technological innovation and growth. Our competitors include…View ↗
Loading...